image credit: Unsplash

Genetic Markers Discovered that Open Door to Potential New Lung Cancer Therapies

Researchers at the Wake Forest School of Medicine, part of Wake Forest Baptist Health, say they have identified a set of new genetic biomarkers that could potentially lead to new personalized treatments for lung cancer. Their study “Recruitment of KMT2C/MLL3 to DNA damage sites mediates DNA damage responses and regulates PARP inhibitor sensitivity in cancer” appears online in Cancer Research.

“When recruited to promoters, histone 3 lysine 4 (H3K4) methyltransferases KMT2 (KMT2A-D) activate transcription by opening chromatin through H3K4 methylation. Here we report that KMT2 mutations occur frequently in non-small cell lung cancer (NSCLC) and are associated with high mutation loads and poor survival,” write the investigators.

Read More on Genetic Engineering and Biotechnology News